Entain mulls sale of international brands to rescue sinking share price March 14, 2024 Entain has reportedly hired advisers including Wall Street boutique advisory Moelis as it considers shredding some of its overseas brands.
John Lewis returns to profit but cuts staff bonus for third year running March 14, 2024 The employee owned John Lewis Partnership (JLP) will again not pay staff a bonus this year, but has reported a return to proft.
Hapag Lloyd profit falls 83 per cent as Red Sea turmoil makes global shipping downturn worse March 14, 2024 Hapag-Lloyd profit fell 83 per cent last year amid a global shipping crisis caused by disruption in the Red Sea.
Alfa Financial posts uptick in profit as it unveils special dividend March 14, 2024 Asset finance software company Alfa Financial Software Holdings has posted an uptick in annual profits while announcing a special dividend as part of plans to return £9.7m to shareholders.
GCP Asset Backed Income proposes shuttering trust March 14, 2024 The debt-focused trust's merger with GCP Infrastructure fell through in September after a "significant minority" of the trust's shareholders said they did not support it, leading to a strategic review.
EU AI Act: What does it mean for UK business post-Brexit? March 14, 2024 The EU AI Act, aimed at controlling AI systems on a risk-based approach, gained an overwhelming majority in favour, with 523 votes.
Bridgepoint reports ‘robust’ investment returns despite tough market conditions March 14, 2024 Private equity firm Bridgepoint has posted an 11.5 per cent rise in underlying pretax profit despite "more challenging, but improving, market conditions".
Trainline shares soar as ticket sales hit £5.3bn on ‘less severe’ rail strike impact March 14, 2024 Trainline shares soared over ten per cent this morning as ticket sales reached £5.3bn, reflecting British rails ongoing post-pandemic recovery.
Vistry launches buyback as revenue boosted by affordable housing push March 14, 2024 Vistry has reported a rise in revenue during the full year as its transition to affordable housing appears to be paying off.
Astrazeneca: Pharma giant snaps up rare disease biotech firm Amoylt March 14, 2024 The acquisition, which is meant to "bolster" Astrazenca's rare disease arm Alexion, brings with it a Phase III investigational therapeutic peptide meant for hypoparathyroidism
